the ceo of allergan thinks so. he'll here to explain why in a fa"fast money" exclusive. >>> plus donald trump sending a chill down corporate america today with this comment. >> companies are not going to leave the united states anymore without consequences. not going to happen. it's not going to happen. i'll tell you right now. >> so what will the consequences be and what could it mean for the trump rally? >>> later, tech continues to tumble, now trading where it was before the election. that has traders hitting the buy button on some battered names. >>> first, stunning news out of starbucks, howard schultz stepping down as chief executive, he will be succeeded by the company's current president, kevin johnson. let's get to andrew sorkin in seattle for all the details. >> reporter: hey, melissa, i am in seattle. howard schultz, the iconic ceo and founder really of starbucks announcing plans to step down effective in april of 2017. he's going to remain at the company, we should say, as executive chairman and plans t

what about a company like allergan or something in that category? is a special pharma name like you said, the product everybody knows about is botox which tends to be a cash purchase. it got hammered when the pfizer deal overseas fell apart. we think it is really cheap, one of the cheapest names in the group. we have a $375 target. today when i was looking it is now in the top 25 in the s&p value index. if money goes towards value, allergan will catch some of the cash coming into the indexes and etf. >> generally speaking when looking at this industry, what would happen if congress decides to side with president trump and take -- and obamacare takes a hit? >> yeah, i think that these names already are trading at valuations that reflect that. so i think where we're buying them we're giving ourselves some safety in terms of free cash flow and the pe ratios, and in a diversified portfolio these look the cheapest to us right now. >> by the same token, what would be the catalyst to move these guys higher? what are you waiting to happen to get to the pric

we'll speak with the chairman and ceo, allergan.g one is a force at the box office -- "rogue one." how much it is expecting to haul in over the weekend. ♪ maria: welcome back. happy thursday, everybody, i'm maria bartiromo. thanks so much for joining us today. it is thursday, december 15th, your top stories 8:30 a.m. on the east coast. the president-elect continuing to meet with high-profile names at trump tower as he looks to fill remaining cabinet positions as he heads to hershey, pennsylvania to continue his thank you tour. it has been an incredible opportunity for all of us to ion witness because they come in and they share their vision and their ideas and their experiences and they help, they love america. they want to help this next administration somewhat in the cabinet and -- maria: very latest as the meeting continues at trump tower today. what did come out of the technology summit yesterday? >>> markets looking to rebound today from yesterday's fed-fueled selloff. futures right around the flat line although we'll probably

back over to you. >> you own allergan. we don't own accorda.around this issue, whether you think these stocks can go in the trump administration? >> well, i think the uncertainty started with hillary's tweet last fall. >> for certain. >> there was some relief when trump was elected. then when he had his comments, they're under pressure again. i think a lot of health care stocks are not overvalued. i think there's interesting opportunities. the question is wiinvestors wai for clarity or not? >> they look to be values across the whole space. it's just if you are getting in front of the potentially more falling knives so to speak that people are a little hesitant to get in because of any sort of political rhetoric that takes these stocks back down. >> i think that you really have to be selective in your stock picking because there are names that are not as dependent on pricing as others. for instance, allergan is a name that i own and continue to own, but it's down 40% year-to-date, and that's because it was just valeant that was dependent on pric

i mean, remember allergan/pfizer got stopped, inversion's more or less had been stopped.nd with the prospect of much lower taxes, why would you move anyway? >> but you know it's funny, i've been able to go around the country a lot in the last couple years and there isn't a town that doesn't have shuttered factories. it got into the consciousness. 95% of the counties voted for trump. and i just think when you go across the country you just see it. you see the abandoned factories. just became part of the psyche. >> and he may be successful in keeping certain jobs here and that would be great. but you and i talk oftentimes about automation. it came up in your interview with greg hayes. came up in your interview yesterday with the gentleman who runs the union there. automation is replacing jobs anyway even at those carrier plants. >> checkers. checkers. no, you get rid of checkers -- remember the self did not work. the self-check hasn't worked, but you get that new checkout and that's a lot of people jobs. why doesn't president-elect trump like these pipelines so much? i mean

we kick it off with allergan. the price target to 274 from 301 mainly because of reduced estimates for its mature products. the analyst is bullish. they met with the management team including the ceo, cfo. they're expecting guidance to be released in february. will differentiate it from other pharmas. also repatriation, that could boost deals. >> large part of it, to be fair, allergan, large part of the business is elected. completely elected. not like the life saving drug needed you got to cut costs like i want to not move my face. second stock, autodesk, upgraded to buy. raises the target. the analyst sesz thaid they got they needed. they see a clear path. they note the design software market finally, their word, moving to the cloud, more cost effective. it is a clear weapon for autodesk. they help make computered aed design, high software. 15% upside it right now. >> 3-d printing play. would you ever get botox? >> who says i haven't? >> third stock, micron technology, big gainer this week, up 8%, with the pullb

if you want a stock that's down a great deal that may be bottoming, i would go with allergan. everybody has given up on it and brent saunders. i think that's a mistake to give on what i believe to be the bottom or within ten points of it. joshua. >> yes. keymar cc. >> it's lightning in a bottle. the stock was down at 3. up 24. up 363%. i would say, late to the party. one more. sharif in florida. >> hello from tallahassee. >> thank you. i am a huge fan. >> thanks a lot. >> what do you think about dqr. >> i think you should be in fang. diamond back energy did an offering tonight. you should buy that one. that's the lightning round! >> announcer: the lightning round is sponsored by td ameritrade. that's a great idea, but why don't you just go to thinkorswim's chat rooms where you can share strategies, ideas, even actual trades with market professionals and thousands of other traders? i know. your brain told my brain before you told my face. mmm, blueberry? tap into the knowledge of other traders on thinkorswim. only at td ameritrade. >>> that's "mad money" for this thursday, have

notably pfizer allergan after that tax inversion crackdown by the u.s. treasury.s blocked, baker hughes halliburton. also also monitor the antitrust regulateders next year. >>> russian news agencies reporting russia plans to expelt 35 u.s. diplomats and ban u.s. diplomatic staff from using warehouses in moscow. this comes in retaliation for u.s. sanctions. we were expecting russia to retaliate. we heard this will be coming. they are taking similar measuring as the u.s. in terms of sanctions. >> the question is will it be exactly tit-for-tat kind of thing or will they pause because they know a new administration is coming. some retaliation there. we'll wait to hear if there's more. >>> top trending stories. new year's eve will be a big night for uber. the company predicting they will hit more than 15 million rides. uber suggesting that riders share rides and plan around the busiest time frame between midnight and 3:00 a.m. >> the big difference with uber now, they have to tell you the price of the journey before you take it. before, you would get off and get an e-m

allergan has shown -- sorry, a lot of appetite, not megamergers, but it has a whole open science approachch it thinks is a great approach to innovation. we won't see anybody like the valeants of this world that essentially rolled companies up. it sort of crashed to earth at 94% of its value. but you'll see people bolting in acquisitions. there may be one more mega merger to come. >> why is it so tough to get drug approvals through 2016? >> the fda would argue that so many came through in 2015, you would naturally expect them to come down. the science and technology is more and more complex and difficult. so the industry is facing difficulty in innovation. that creates more m&a as well. does it change your mindset about how you look at the sector? typically you look at the pine li pipelines, see what's coming into the mix. you should be look at distribution deals, the likes of johnson & johnson with actelion to move the needle? >> people have to find global reach in some way or other. and, you would argue that some companies are trying to cover every region, every country. i think there's

we want growth, and the one that has the most is the one that my charitable trust owns, which is allergan're not done. we're taking one more. we're going to sam in illinois, sam. >> caller: professor cramer, booyah and happy holidays to ya. >> merry christmas, what's happening? >> caller: cxw. >> no. we're worried about the private jails. we think they're moving up too much. we're going to stay away. but i do say that this one's a little cheaper than some of the others we've profiled. let's go to anthony in new york, anthony. >> caller: hello, jim. booyah and happy holidays to you and your family. >> same. >> caller: my stock is ash. >> people don't like ashland but i like it because it's international. it is very, very shareholder friendly, and that, ladies and gentlemen, is the last lightning round we will ever have with kyle. we'll do it again. >> one, two, three. >> stay with cramer! [ buzzer ] >> announcer: the lightning round is sponsored by td ameritrade. hey gary, what are you doing? oh hey john, i'm connecting our brains so we can share our amazing trading knowledge. that's a gre

we're seeing allergan's ceo come out with a pledge, among other things, not to raise drug prices by morehan 10% a year. n nortis has come out with a pledge make sure the government doesn't come in and say we'll self-regulate. we promise not to raise drug prices by more than 10% a year. whether this will be enough is what the whole industry is trying to figure out right now, guys. >> watching the stocks. meg terrell with the latest for us there. thanks, meg. let's bring in chris meekans, covering health care policy. welcome him in from virginia today. chris, welcome. >> people were digesting these words from mr. trump, you said to ignore them. why? >> there are really three reasons. one, personnel is policy. his appointments, the key positions matter way more than what he might tweet about or what he might say in some interview to a loaded question. i'll get to that in a sec. you know, if you look at who he appointed, congressman tom kreiss is a free market traditional republican. he is opposed medicare negotiating drug prices. he has opposed medicare part b drug demo. this is a guy who b

would allergan being a good fit for valeant? >> i won't speculate on that particular question. i would simply say that as we look at it we are going to stay focussed. we will stay focussed on the core products on dermatology business, more of a niche product. we will focus on eye care. that is a focus for us. we are going to focus on gi, gastrointestinal drug. i think plus consumer business will be the core. i am excited to keep going forward and '17 will be a new year for us. >> what is your relationship like for new shareholders? bill acman give you a heads up? >> bill has been wonderful shareholders and part of our board of directors. they have great comments and have been helpful to me. certainly it has been a chance to really rebuild the team, rebuild the product portfolio especially new products and take activities to try to pay down debt. we are going to operationally improvement but we are looking at noncore assets. that is something we have been working closely with bill. >> scott has a question. >> it's good to talk to you. you mentioned salex as being an important pr

and allergan.ocks opened this morning, the dow began gaining steam and dow 20,000 hoopla was back in vogue. and then the buying dried up. now back to bob on the floor of the nyse. is anybody give a reason? i heard concerns over china growth. maybe we'll talk about that, higher oil. what is the reason that the buyers have fled? >> we're so used to having the dow go up or going sideways that when you get a day like this, pretty nottest decline in t emo dow -- we have a simply classic low volume sell-off. extremely low volume. even for a holiday weekend. so there has not been any leadership in the dow or in the major sectors for two weeks in a row. now there is not any buying interest. that's a perfect combination for a drift lower, exactly what we're seeing today. when i say lack of leadership, put up the dow leaders here. we have no leadership with industrials like caterpillar. we don't have leadership with tech like intel, consumers like disney haven't been doing anything. most disappointing, exxon

but i'm very tempted to add, i own a little bit of allergan, lexion, i own the right companies but the sentiment is so terrible. >> thank you for joining us. donald trump expected to pick fast food ceo andy puzder as his secretary of labor. he's against raising the minimum wage to 15 bucks. what the fast food ceo could mean for america's job markets next. there's just 23 days left in the year. how should you be positioned to minimize the tax burden or your winning investments? is happening before r eyes. shift in human history sixty to seventy million people are moving to cities every yr. at pgim we help investors see the imications of long term megatrends like the prime time of urban expansion, npointing opportunities to capture alpha in real estate, infrastructure. partner with pgim the globalnvestment managent >>> welcome back. donald trump's cabinet is slowly taking shape and he's expected to fill another spot shortly. andy puzder is reportedly up for the job as labor secretary. john harwood joins us from outside trump tower in new york city and what this would mean for the labor m

allergan up 2%. buying life sell. it is the 12th deal this year. >>> goldman sachs has been the single biggest driver to dow 20,000. or 19,98. the stock is up nearly 50% just since october 1st. but keep this in mind, goldman has not even a public company, with a dow hitting 10,000 for first time. dominic chu joining us with some of the major changes between dow 10k and dow almost 20k. >> like a slow grind higher. it just goes to show you what the dow looked like today versus what it looked like back then. let's take you into the time capsule and back in time versus now. if you look at some of the notable components and some notable companies that were added to the dow since 10 ,000, since march of 1999, had basically nike. we talk about that stock, the other stock besides coca-cola in the red this year in the dow. goldman sachs, public company, wasn't back then. united health, apple, home depot, microsoft, blue chips in their industries. and the reason why they are part of the dow today. look at the notable deletions

it is odd because allergan is a pharmaceutical company and while i was there started losing my vision. i came to the san francisco bay area when i could go longer drive because i diwant my life to be over and i-but i-the only thing i couldn't doot the time is drive. i could still work and so insed of working for a pharmaceutical company because i moved to the city, what a great city for transs portation i didn't to-catch a bus to catch a bart and shuttle. i decided to go to executive recruitjug i came in 1997 and began my career as a executive recruiter so i have been fortunate enough to work in the city with many of the large corporations for many years. that is why i think that i'm the luckiest person in the world because it was just serendipitous that my life was able to do continue doing what i was doing before but serving the community i became a part of. thank you joannea. sorry? >> that is quhie i wanted to you to tell your sorry because through that wealth of experience and being able to reshape it and service to the community is what is really important and you know, earlier

. >> for those who may not know, what is the brent saunders who is the ceo of allergan pledged?no double digit. just kind of just being what most people would say is reasonable if you're selling tide or proctor for non-innovation, for brand new drugs, yes. but if you're just going to make the same thing over and over again and raise the price, that's strucken -- >> have we done sld yet? >> oh, yes, sears. >> narrower than expected but fifth straight quarter of a loss. >> not an inflection point there. >> comps down 7.4. no more talk of profitability. >> i don't know what to say about that one. you know, home appliances, consumer electronics, apparel weak, what else is there? home appliance is home depot gaining from them according to the fabulous cfo. sears minus ten. still talking about monetization, david -- you know what dies hard? the notion they're going to monetize die hard. it's like die hard 7, right? remember? >> i do. what did we end, four or five? >> there's a new one called christmas party, i think that's die hard one that's a sequal. >> $1.2 billion market value if

the way, drugmakers definitely the laggard today, almost every s&p loser at the worst is a mylan, allergan, cardinal, abbott, merck, amgen, right? >> yeah. normally would move that stock, heavily shorted stock. >> comments "time" magazine indicated drug prices too high. quickly i wanted to do a short follow-up on my story last week about pandora just to add a little bit there. pandora is taking a strategy -- it's very early by the way in terms of potential sale of this company. i want to share they're looking at other potential acquirers beyond sirius so they can have leverage if and when sirius comes there that door with serious negotiations with a battle potential. it doesn't mean they're going to find other potential buyers, but that is the strategy at this point and certainly wanted to share it. is there an apple? you said no, most likely, jim, or google or any others out there who might consider buying the service. certainly that would give them some leverage in negotiations that will begin with sirius at some point many expect. early days again but wanted to share that nugget based o

none bigger than allergan and pfizer. remember that? the u.s.saying we have devised new inversion regulations basically pinpointed to stop this transaction. and they did just that. baker hughes, halliburton of course antitrust a big theme over the course of this last year. it showed its fangs in the case of baker hughes and halliburton and office depot, staples, williams, ete, that fell apart because the industry basically fell apart. those were some of the bigger deals that did not make it to the finish line. also some failed bear hugs. it is not easy to get a hostile deal done, united technologies and honeywell of course was one of my favorites because i broke it, but didn't happen. honeywell tried for weeks, famous interview of course with the ceo of united technologies greg hayes saying ain't going to happen. mondelez and hershey, that didn't happen as well, sara's favorite. but what about next year? what about the animal spirits we've seen? what about the confidence of ceos in a less regulatory invasive environment? listen to a guest i had

allergan is promising to limit price increases.he industry try to take some steps, kind of self police, a look for solutions on prices. i think they are aware that if they do not do something here, this could easily become a political issue, even under trump. we have talked about this as a populist issue, and he is showing that he is trying to be a populist president. david: the congressman coming in for hhs has wanted to privatize it, turn it back into a free market. will that give reassurance? drew: it is interesting. there is a difference from where trump has been and where republicans have traditionally been on this stuff. republicans have said, hey, let the industry do what it well, do not negotiate prices. trump is not necessarily in line with those views. so we could see a reset from the traditional political postures on drug prices. david: thanks so much. that is drew armstrong. bell is uppening next on "bloomberg daybreak," about four minutes away. dad and spicy being futures slightly higher. the ftse is positive -- the do

quick break, take a look at shares of mylan rising after the drugmaker launched generic version of allergan's, drug used by women to prevent pregnancy. much more ahead on "squawk on the street." mylan up 1.3%, market just above flat for this hour. nothinintimidas janelle. not boys... t worms. not cancer. i nt you on my team. ok. janelle's doctors turned to st. jude children's i nresearch hospital where we've helped increase the overall childhood cancer survival rate f20% 80%. we will not stop until we hit00 cancer, u're going down. and jalle, you're growing u donate now at stjuderg orhowhere see the . jude logo. >>> welcome back. now let's get to the cme group. rick santelli with the santelli exchange. rick. >> thank you, wilfred. like to we can my second to last guest of the year, jim bianco. >> i'll take it. >> there we go. jim, for 2017, two issues i would like your opinion on capital outflows from countries like china and the european union. and, b, how the world of passive investing in etfs may harbor some secrets for 2017. >> i think you're going to see capital outflows from europe and

a tweet, a vicious tweet from trump after reading brent saunders' allergan piece, again, something newabout. >> indeed. speaking of big cap pharma, barron's has a list of top stocks for next year, their favorite ten. merck's one of them along with alphabet, apple, citi, delta, disney, unilever, toll. >> merck has been so underrated ever since ketruda, a better drug for cancer perhaps -- many different cancers than opdivo. i like that list but my problem is if you're a globalist, you may be thinking incorrectly about the new white house. because they're not globalists. they want ceos from america to think about america first. and then the global markets. as opposed to globalist ceos who live in america. i know that sounds like all i'm doing is an anagram, but it's not an anagram. it's about new policy. >> jim, as we're talking, amazon has unveiled a new product called amazon go. >> i want it. i got to find out what it is first. >> a new kind of store, they say, with no checkout required. you'd never wait in line, you walk out. you use an app to enter the store, you take the products you

allergan and procter & gamble something they have potential ahead.t all of the lack of movement could come to an end will come to an end at some point in 2017. this is g #btv 5474. if the year-to-date chart of the vix. the fear gauge is trading near all-time lows, but it also has been a volatile year, spiking up and down. the last couple of times we have seen this bottoming process, it has moved higher is volatility has moved up and stocks have dropped. scarlet: thank you, abigail doolittle. let's get a check of the bloomberg first word news. courtney collins has more from the newsroom. saysney: after kia airways the men who hijacked a plane ended up in multiple because of fuel limitations. pastorsiverted with 111 -- passengers and six crew members on board. when the airplane reached 36,000 feet, the pilot received a wasnd to land in rome and told by another crew member the hijackers were armed. the pilot proposed leading in tripoli, but the hijackers decided malta was the next best option. the hijackers surrendered to malta authorities. meanwhile, g